Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	KOPECKY Jindrich KUBECEK Ondrej BUCHLER Tomas MELICHAR Bohuslav POPRACH Alexandr ZEMANOVA Milada KATOLICKA Jana KISS Igor HAJEK Jaroslav STUDENTOVA Hana SPISAROVA Martina
Rok publikování	2021
Druh	Článek v odborném periodiku
Časopis / Zdroj	In vivo
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://iv.iiarjournals.org/content/35/5/2981
Doi	http://dx.doi.org/10.21873/invivo.12593
Klíčová slova	Renal cell cancer; nivolumab; mTOR inhibitor; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; systematic inflammation index
Popis	Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.